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Abstract
Background: The etiology of pre-eclampsia (PE) is unknown; but it is accepted that normal pregnancy represents a
distinctive challenge to the maternal immune system. C-reactive protein is a prominent component of the innate immune
system; and we previously reported an association between PE and the CRP polymorphism, rs1205. Our aim was to explore
the effects of additional CRP variants. The IBC (Cardiochip) genotyping microarray focuses on candidate genes and
pathways related to the pathophysiology of cardiovascular disease.
Methods: This study recruited 140 cases of PE and 270 matched controls, of which 95 cases met criteria as severe PE, from
an American Indian community. IBC array genotypes from 10 suitable CRP SNPs were analyzed. A replication sample of 178
cases and 427 controls of European ancestry was also genotyped.
Results: A nominally significant difference (p value ,0.05) was seen in the distribution of discordant matched pairs for
rs3093068; and Bonferroni corrected differences (P,0.005) were seen for rs876538, rs2794521, and rs3091244. Univariate
conditional logistic regression odds ratios (OR) were nominally significant for rs3093068 and rs876538 models only.
Multivariate logistic models with adjustment for mother’s age, nulliparity and BMI attenuated the effect (OR 1.58, P=0.066,
95% CI 0.97–2.58) for rs876538 and (OR 2.59, P=0.050, 95% CI 1.00–6.68) for rs3093068. An additive risk score of the above
two risk genotypes shows a multivariate adjusted OR of 2.04 (P=0.013, 95% CI 1.16–3.56). The replication sample also
demonstrated significant association between PE and the rs876538 allele (OR=1.55, P=0.01, 95% CI 2.16–1.10). We also
show putative functionality for the rs876538 and rs3093068 CRP variants.
Conclusion: The CRP variants, rs876538 and rs3093068, previously associated with other cardiovascular disease phenotypes,
show suggestive association with PE in this American Indian population, further supporting a possible role for CRP in PE.
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Introduction
Pre-eclampsia (PE) is a pathologic condition of pregnancy
characterized by the onset of hypertension and proteinuria after 20
weeks of gestation.[1,2] It has been called a ‘‘disease of
theories’’[3,4] due to multiple putative etiologies and risk factors;
but placental ischemia seems to play a central role in the
pathogenesis, which involves an imbalance of circulating angio-
genic factors and endothelial dysfunction.[5,6] The underlying
cause of this ischemia remains unknown; however pregnancy has
long been recognized as a distinctive challenge to the maternal
immune system. Maladaptive responses to this immune challenge
are frequently postulated as primary initiators of the multiple
subsequent pathways leading to PE. [7,8]
Although there is significant phenotypic heterogeneity across
the spectrum of PE, a number of studies have shown a 2–5 fold
increase in risk amongst first-degree relatives of women with
PE.[9–12] Twin studies estimate the heritable component of PE to
be .50% with high concordance for PE amongst mono-zygotic
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that 35% of the variance in PE was attributable to maternal
genetic effects, 20% to fetal genetic effects (with similar
contribution of maternal and paternal genetic effects), 13% to
the ‘couple effect, and 32% to unmeasured factors.[14] Autosomal
dominant inheritance with 50% penetrance or multifactorial
causation, matrilineal and mitochondrial inheritance have also
been proposed as a plausible models of inheritance.[11,15] A
variety of genetic approaches have been applied to the study of PE
including linkage analysis and candidate gene studies. Whole-
genome linkage screens revealed at least eight chromosomal
regions affecting PE transmission.[16–18] Delineating the 2q22
linkage peak revealed variants in the ACVR2A locus to be
associated with PE in a Norwegian PE population.[19] Johnson
and colleagues have also resolved a linkage signal in Chromosome
5q, demonstrating association of ARTS-1 in one of the few large
well powered PE studies.[20] Founds et al. (2009) reported
evidence in early pregnancy of dysregulated genes associated with
immune function in chorionic villus sampling (CVS) tissues.[21]
Most PE candidate gene association studies have focused on genes
relating to: (a) renin–angiotensin system; (b) coagulation factors; (c)
oxidative stress pathways; (d) dyslipidemia; and (e) immunoregu-
latory components, in particular within the HLA region. The
incidence of PE is frequently reported to be approximately 5–8%
of pregnancies.[22] in most populations; but the only systematic
assessment in an American Indian population found a prevalence
of 9.1% among pregnancies in the Navajo Nation.[23] Signifi-
cantly higher rates of hypertensive disorders of pregnancy in
women of African American versus European ancestry have been
observed.[24]
C-reactive protein (CRP) is a prominent component of the
innate immune system[25]; and has been employed as a non-
specific measure of inflammatory status in epidemiologic studies of
cardiovascular disease (CVD).[26] Although the expression of
CRP in relation to the etiology and clinical severity of both
hypertension and PE has been examined extensively [27–30];
there has been a lack of information on the possible association
between genetic variants of CRP and PE.
Previously we demonstrated an association between rs1205 in
CRP and severe PE in an American Indian cohort;[31] and the
present study was undertaken to determine if other genetic
variants of CRP captured on the IBC array are correlated with risk
or severity of PE within this higher risk population.
Methods
Study recruitments and Ethical Approval
Turtle Mountain Community College (TMCC). Approval
was obtained from the Aberdeen Area IHS and University of
North Dakota Institutional Review Boards (IRBs) and the tribal
government. Written informed consent was obtained from each
participant.
Boston study. The Institutional Review Board (IRB) of
record for Massachusetts General Hospital and Brigham and
Women’s Hospital is Partners Human Research Committee; and
for Beth Israel Deaconess Medical Center it is the Committee on
Clinical Investigations. With IRB approval, the billing records of
patients delivered at Massachusetts General Hospital and Brigham
and Women’s Hospital from 1995–2011 were queried for ICD9
codes suggestive of PE. Whenever a PE patient returned to a
Partner’s Hospital, blood samples at their point of discard (after
completion of all clinical diagnostic testing) were collected for
genetic analysis. Cases were validated for PE and its severity by
electronic medical record/chart review in a 30 day time-limited
link to protected health information. After links to protected health
information were deleted, extracted DNAs of accessioned samples
were released to the study staff in a de-identified manner for
further investigation. Because the investigators do not interact with
any individuals for the ascertainment of data or samples, informed
consent was not obtained: the Partners Human Research
Committee elected to waive the requirement to seek informed
consent (as detailed by 45 CFR 46.116). The participants from
Beth Israel Deaconess Medical Center provided written, informed
consent.
Philadelphia study. The Children’s Hospital of Philadelphia
(CHOP) IRB approved DNA collection from 73 mothers with PE
and 353 control normotensive mothers from 2009–2012 at the
Center for Applied Genomics (CAG) at CHOP through the Study
of the Genetic Causes of Complex Pediatric Disorders (GCPD).
Mothers of recruited children were asked between 2009–2012 if
they had ever had PE during their pregnancy and gave written
informed consent and HIPAA authorization to allow access to
their medical records.
Recruitment for the TMCC case and matched control study has
been ongoing from 8/04 to 7/12. The federally funded Indian
Health Service (IHS), through the hospital and clinic located in
Belcourt, North Dakota, is the primary health care provider for
eligible tribal members of the Turtle Mountain Band of Chippewa.
Most potential cases (,80%) were identified by automated query
of an electronic medical record database (the Resource, Patient,
Management System [RPMS]) at this facility, using a relevant
group of ICD9 codes, designed to be inclusive. Additional
potential cases (,20%) were ‘‘self-identified’’ among family
members and acquaintances of cases and during the recruiting
of controls.
The medical records of all potential cases were abstracted for 78
clinically relevant factors, including the highest of up to 3 blood
pressure (BP) measures between 20 weeks of gestation and 30 days
postpartum and the highest of up to 2 measures of proteinuria in
the same period. Cases were verified as meeting diagnostic criteria
for PE if at least 2 of the following were identified:
1) At least 3 BP values above either 140 mmHg systolic or
90 mmHg diastolic; and absence of a diagnosis of, or
treatment for hypertension (during the year prior to
conception and the first 20 weeks of gestation).
2) Proteinuria as indicated by a 24 hour excretion of .300 mg,
or at least two +1 dipstick measurements in the absence of
prior proteinuria.
3) A diagnosis of PE, eclampsia, or the hemolysis, elevated liver
enzymes, low platelet (HELLP) syndrome by an attending
physician after 20 weeks of gestation.
These criteria were chosen to be compatible with the NHLBI
Working Group on Research on Hypertension in Pregnancy
(Working Group) definition [32] and to also consider the clinical
judgment of the attending physician. Since the present study uses a
retrospective, case/control design, it was not possible to mandate
specific measures at defined intervals. The cases and controls were
ascertained from records spanning more than 15 years and
including over 6 facilities. It should be noted that the present study
criteria include repeat measures, which while recommended and
encouraged, are not strictly required according to the Working
Group[32] or the American Society of Hypertension (ASH).[33]
These advisory groups have also stressed the need for careful
attention to subjective symptoms and less common signs. For all of
these reasons, it seems justified to give partial weight to the
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quantified measures.
Controls were ascertained by contact of the first individual to
deliver before and after the index case. If a potential control
declined participation, the woman delivering during the next prior
or subsequent day was contacted; and this was continued until two
controls were recruited, one before and one after the index case.
This method of ascertaining controls was chosen as a convenient
means of randomization and to control for possible seasonal
influences on PE.[34] Some participants had been recruited from
the prenatal clinic at this facility as part of an anticipated
longitudinal cohort, which became impractical. After criteria for
control status was confirmed, they were matched by date of
delivery as closely as possible to previously identified cases, up to a
maximum of 3 months from the index case. These additional
controls involved 65 (24%) of the pairs. Of these alternatively
recruited controls, 50 (77%) were matched to within 30 days of
their case and only 4 differed by more than 60 days (1 control a
maximum of 72 days) from their case. As a group these additional
controls differed from their cases by an average of 18.57 days,
compared with 9.39 days (p,0.001) for the originally matched
pairs. The available medical records of all controls were abstracted
in the same way as cases; and matching of controls was entirely
blinded to genotype. It was verified that these individuals did not
meet criteria for PE. Birth certificate data were also obtained for
case/control participants to more uniformly ascertain data on such
factors as smoking, alcohol intake and educational attainment.
Replication analysis was conducted on two groups assembled
for a larger collaborative study, comprised of:
1) The Boston area Pre-eclampsia Genetics Collection (three
Harvard affiliated hospitals).
Samples meeting ACOG 2002 criteria were included in the
study (88 cases). Blood from 17 additional cases based on physician
diagnosis and 74 normal term controls were collected from
patients at the Beth Israel Deaconess Medical Center.
2) Children’s Hospital of Philadelphia Pre-eclampsia Genetics
Collection.
The definition of PE employed is defined as onset hypertension
after 20 weeks of gestation with systolic BP$140 or diastolic
BP$90 on two occasions at least 6 hours apart in the presence of
proteinuria of 300 mg/dL on a 24 hour collection or at least +1o n
a dipstick.
For the American Indian population, prior to January of 2009,
template DNA was provided by capillary blood samples collected
on ‘‘FTA Classic Cards’’ (Whatman Inc) paper. Three 1.2 mm
diameter ‘‘pellets’’ were punched from the cards and processed
according to the manufacturer’s recommendations. Recently
template DNA has been collected and processed using salivary
samples and the Oragene (DNA Genotek Inc) system; and the
majority of those with capillary samples were re-consented and an
additional salivary sample obtained. For genotyping of the
replication cohort, DNA was extracted from blood or saliva using
standard alkaline lysis methodologies and stored at 220uC.
Genotyping was accomplished primarily (319 of 410 (78%) total
samples) by microarray analysis on the ITMAT/Broad/CARe
(IBCv1) at The Center for Applied Genomics at CHOP. This
genotyping microarray selected .49,000 SNPs related to ,2,000
genes and was guided by genome-wide association study data,
pathway based approaches and comprehensive literature searches
to variants with known relevance to cardiovascular, metabolic and
inflammatory pathology.[35] Quality control standards were
monitored with the mean call rate above 98% for all SNPs on
the microarray and less than 4% of samples had a SNP call rate
below 95%. The call rates for rs876538 and rs3093068 were 100%
and 95.3% respectively. Twenty four samples were genotyped for
the rs876538 variant with both the IBC array and TaqMan (Life
Technologies) with no discordant results observed.
Results of the microarray genotyping will be available to
qualified investigators with assurances that 1) no attempts will be
made to identify individuals, 2) goals of the analysis are within the
scope of the consent and 3) the results will not be used for
commercial purposes.
The remainder of the samples without salivary DNA were
genotyped using pre-designed TaqMan genotyping assays and
protocols were implemented for SNPs on a real-time, Mini-
Opticon (Bio-Rad Laboratories Inc), four color thermocycler.
Controls were identified for at least two of the three possible
genotypes (and ‘‘blank’’ controls) for each SNP were included with
each analysis. Control material of consistent genotype (replicated a
minimum of ten times) for each genotype was run with each set of
samples. In the case of rs876538, HapMap genotypes from eight
Coriell Institute reference samples were confirmed in our
laboratory.
The replication genotyping for this study, European ancestry
samples from Boston and Pennsylvania (n=605), was also
conducted on the IBC array with principal components analysis
performed using standard Eigenstrat pipelines.[36] Quality control
criteria included filtering of samples with ,90% call rate (0
removed) and SNPs with ,90% call rate, minor allele frequency
,1% or departure from Hardy Weinberg equilibrium with
P,10
26. The rs1205 and rs876538 variants passed quality control
but rs3093068 failed within this replication sample, therefore we
used the proxy rs1206785 (r
2=1 with rs3093068 in 1000
Genomes project [1KGP] CEU population).[37] Overall, 178
cases and 427 controls were available for association analysis
within the replication population.
The primary analysis of the American Indian samples chose all
24 CRP SNPs available on the IBCv1 array. Of these, eight were
observed to be monomorphic in this population and another five
were excluded for low prevalence. Another SNP exhibited a call
rate of 60% and was considered unreliable for analysis, leaving ten
SNPs remaining for analyses.
Statistical analysis was primarily carried out using SPSS version
10.1.0 software, with Egret version 2.0.31 used for the logistic
regression analysis. Descriptive statistics report mean (+/2 SD) for
continuous variables and proportions with 95% CI for discrete
variables. HWE analysis was assessed using standard chi-square
methods. Due to the matched nature of case/control pairs,
McNemar chi square analysis is required for genotype compar-
isons; and relies on evaluation of the two opposing sets of
discordant genotypes. The null hypothesis holds that there should
be equal numbers of discordant pairs where the case has genotype
A and the matched control has genotype B; compared with the
opposite situation, where the case has genotype B and the control,
genotype A. The genotype risk score for McNemar analysis
considered the presence of either identified risk genotype,
rs3093068 (G allele dominant) or rs876538 (C allele recessive),
among pairs with both alleles available. The risk score for logistic
regression analysis used a more powerful, ordinal variable, where
both risk genotypes =2, either =1, and none =0. This ordinal
risk score could not be used for the McNemar paired analysis
because the available software will not support it and many
statistical texts consider this analysis ‘‘beyond their scope’’.
Conditional logistic regression was used to explore the multivariate
association of genotype and other variables with risk of PE.
Statistical significance was set at P#0.05, and study-wide statistical
CRP Gene Variants Associated with Pre-Eclampsia
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component analysis was conducted using ancestry informative
SNPs from the IBCv1 microarray.
The replication analysis was performed using logistic regression
with SNPs coded in an additive genetic model, and with
adjustment for study site and 10 principal components computed
as described above to correct for population structure.
Genomic characterisation and SNP functional analysis
The extended locus around each associated SNP was defined by
identification of all SNPs showing r
2 LD.0.5. LD was defined in
the three HapMap population groups using the HaploReg tool
which includes LD data derived from Phase I 1000 genomes
project. Population groups were CEU (Utah Residents (CEPH)
with Northern and Western European ancestry), ASN (Han
Chinese in Bejing, China; JPT Japanese in Tokyo, Japan; CHS
Southern Han Chinese; CDX Chinese Dai in Xishuangbanna,
China; KHV Kinh in Ho Chi Minh City, Vietnam) and AMR
(MXL Mexican Ancestry from Los Angeles USA; PUR Puerto
Ricans from Puerto Rico; CLM Colombians from Medellin,
Colombia; PEL Peruvians from Lima, Peru). The full genomic
context of the CRP locus defined by this process is shown in
Figures S1 and S2 and the SNPs identified in this region are shown
in Table S1. The putative functional impact of associated SNP
signals were investigated using a combination of HaploReg [38]
and Regulomedb[39], which both draw on comprehensive data
from the Encyclopedia of DNA Elements (ENCODE), including
published eQTL studies.[40] All SNPs identified in LD with the
associated variants were visualized in the UCSC human genome
browser.
Results
Among the 140 cases of the discovery sample, 52 (37%) utilized
the clinical diagnosis as one of only two qualifying criteria. Of
these 52, all but 11 (8%) would have met either the minimal
standards for BP or proteinuria of the Working Group or ASH;
and all of those 11 met at least the more stringent BP/proteinuria
standard of the current study, in addition to a clinical diagnosis of
PE. Five of these 52 cases also had objective signs of end organ
involvement as defined below and three had seizures.
At least one of the American College of Obstetricians and
Gynecologists’ (ACOG) defining criteria [41] for severe PE was
met by 95 (68%) cases. These criteria require two BP measures
over 160 systolic or 110 diastolic, separated by at least 6 hours;
and proteinuria exceeding 5 grams in 24 hours or 3+ by dipstick
on two occasions. Of those with severe PE, 84 (88%) had at least
two BP measurements over 160 systolic or 110 diastolic, 22 (23%)
met the 3+ proteinuria by dipstick or over 5 gm per 24 hour
criteria, and 16 (17%) individuals met both criteria. In the context
of a hypertensive pregnancy, an additional 5 cases had a
combination or any one of: platelets less than 100,000/mm
3,
creatinine greater than 1.3 mg/dl, liver transaminases over two
times the upper limit of normal for the hospital laboratory, or
experienced a seizure during parturition, also meeting criteria for
severe PE.
Table 1 summarizes the SNPs tested, population prevalence and
consistency with HWE among cases and controls combined. None
of the SNPs tested showed significant deviation from HWE. As the
design of the IBC array captured specific CVD-related SNPs from
the previous literature, as well as tagged all common variation
across CRP, all of the SNPs (except rs3093070 – which had
design/synthesis issues) have been captured.
Pertinent characteristics of all paired cases and controls are
summarized in Table 2. Of the ten SNPs studied, rs2794521 and
rs876538 revealed nominally significant association (P,0.05),
whereas rs3091244 and rs3093068 showed marginally significant
differences between cases and controls. When comparing allelic
frequency of severe PE cases and controls, none of the SNPs
retained significance. Significant differences between all cases and
controls were noted for nulliparity, weeks of gestation at delivery,
body mass index (BMI), gestational diabetes, weight at first
prenatal visit, and both systolic and diastolic blood pressure.
Table 1. Characteristics of SNPs studied and study population prevalences.
dbSNP ID Physical position (bp)Alleles, functional effect Minor allele frequency 95% CI
Hardy-Weinberg
(p value)
rs12068753 159692537 T/A, 59 UTR A=5.8% 4.1–7.6 0.251
rs1341665 159691559 G/A, 59 UTR A=44.9% 41.0–48.7 0.443
rs12084589 159688441 C/A, 59 UTR A=5.7% 4.0–7.4 0.263
rs3093059 159685136 T/C, 59 UTR C=5.8% 4.1–7.6 0.251
rs2794521 159685096 T/C, 59 UTR C=21.7% 18.5–24.9 0.101
rs3091244 159684665 C/T, 59 UTR T=30.2% 26.7–33.6 0.698
rs1800947 159683438 C/G, coding, synon G=4.0% 2.5–5.5 0.517
rs3093068 159681364 C/G, 39 UTR G=5.9% 4.1–7.8 0.252
rs3093070 159680817 A/C, 39 UTR C=0.8% 0.1–1.5 0.885
rs876538 159675717 C/T, 39 UTR T=18.4% 15.8–20.9 0.206
Boston and Philadelphia replication cohort
dbSNP ID alleles,functional effect Minor allele frequency 95% CI Hardy-Weinberg (p
value)
rs 12068753 proxy for
rs3093068
159692537 T/A, 59 UTR A=7% 5.2–8.8 1.00
rs876538 159675717 C/T, 39 UTR T=21% 18.2–23.8 0.14
rs1205 159682233 C/T, 39 UTR T=35% 31.7–38.3 0.36
doi:10.1371/journal.pone.0071231.t001
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were not included in further models and felt likely to be
consequences of PE or the applied diagnostic criteria, rather than
etiologic. Principal component analysis of the ten vectors showed
no significant difference between cases and controls.
Table 3 shows the genotypic results of paired cases and controls.
The number of pairs with discordant genotype and the total
number of pairs analyzed is shown for each of the 10 SNPs tested
in both the total cohort and in the severe PE subset. McNemar
chi-square analysis of pair wise comparisons (major allele
dominant, minor allele dominant) demonstrates nominally signif-
icant associations for all cases of rs3093068 (G dominant), and
Bonferroni adjusted, significant associations for rs2794521 (C
dominant), rs3091244 (C dominant), and rs876538 (C recessive)
and the dichotomous risk score including those with either
genotype, with chi square, 1 df, values ranging from 8.22 to
16.83 (P=4 610
25). For analyses considering only severe cases, the
only comparisons that retained significance were rs876538 (C
recessive), nominal; and the dichotomous risk score (P,0.0001),
significant after Bonferroni adjustment. The two SNPs of primary
interest are modestly correlated with each other (r
2=0.014,
D9=1.0) and with rs1205 (r
2=0.03, D9=0.84 for rs3093068 and
r
2=0.16, D9=0.97 for rs876538).
Univariate conditional logistic regression results are shown in
Table 4 and confirm frequently reported associations between
nulliparous status, maternal obesity and infant birth weight.
[33,34] Gestational diabetes also showed a significant association
with PE in univariate analysis; but lacked significance (P=0.117)
when included in a multivariate model with age at delivery,
nulliparity and BMI. The SNP rs876538 showed nominal
significance in analysis of all cases; and the additive risk score
was nearly significant with a Bonferroni adjusted p value of 0.009,
whereas rs2794521, rs3091244, and rs3093068, demonstrated
only marginal significance (P=0.068, p=0.078, P=0.063 respec-
tively) in univariate analysis. Models utilizing multivariate
conditional logistic regression (Table 5) continued to show robust,
independent effects of nulliparity and obesity. Since age is clearly
related to nulliparity, inclusion in multivariate models was deemed
necessary, although models without showed very similar results.
Multivariate models of the individual SNP genotypes were
attenuated to marginal significance for rs2794521 and rs876538
(both P=0.066). The additive risk score showed nominally
significant association with PE among all cases and controls
(P=0.016).
Univariate analysis of the 95 cases meeting the definition of
severe PE and their 186 matched controls did not change any of
the previously mentioned univariate relationships with clinical
factors; and now showed nominally significant association with
rs3093068 (OR 2.37, P=0.04, 95%CI 1.03–5.42); but not with
any of the other single SNPs genotypes. The additive risk score
demonstrated nominal significance (OR 1.82, P=0.012, 95%CI
1.14–2.91). Multivariate conditional logistic regression results
showed marginal, independent association for rs3093068,
p=0.050, but lack of significance for the other individual SNPs.
The additive risk score attained nominal significance, with an
OR=2.03, p=0.013, and 95% CI 1.16–3.56.
Univariate replication results in the Boston and Philadelphia
sample of European ancestry are shown at the bottom of Table 4.
We observed significant replication of SNP rs876538 T with PE
(OR (95% CI) 0.65 (0.46–0.90) p=0.0109 for the minor T allele).
T allele frequency was similar to the frequency observed in
American Indians. No association of SNP rs1205 or rs12068753
was observed with risk of PE.
Review of LD with the associated SNPs rs876538 and
rs3093068 identified 55, 32 and 39 variants showing LD
(r
2.0.5), in HapMap CEU, ASN and AMR populations
Table 2. Characteristics of matched cases and controls.
Characteristic Cases Controls p value
Number (N) 140 270 N/A
rs2794521, C allele freq 41/201*=16.9% 92/254=26.6% 0.008**
rs3091244, T allele freq 87/169=34.0% 101/281=26.4% 0.050
rs3093068, G allele freq 20/246=8.1% 16/366=4.4% 0.078
rs876538, T allele freq 40/280=14.3% 119/440=27% 0.010
Age, mean years (SD) 23.88 (6.4) 23.74 (5.40) 0.768***
Parity (N,% nulliparous) 94/140 (67.1%) 114/270 (42.2%) ,0.001****
Weight at first prenatal 181.7 (46.82) 161.6 (41.35) ,0.001***
Body-Mass index (BMI) 30.92 (7.39) 27.42 (6.88) ,0.001***
Gestational diabetes, N (% yes) 15/122 (12.3%) 9/199 (4.8%) 0.031****
Weeks of gestation at delivery 36.67 (3.96) 39.52 (1.82) ,0.001***
Birth weight of infant, grams 3013 (967) 3431 (623) ,0.001***
Mother’s educational attainment (years of education) 11.95 (1.85) 12.15 (2.44) 0.405***
Maternal smoking, N (% yes) 38/95 (40.0%) 76/160 (47.5%) 0.543****
Maternal smoking (Mean cigarettes smoked) 6.75 (18.03) 10.51 (23.20) 0.047***
Mean systolic blood pressure 163.8 (18.3) 132.9 (12.9) ,0.001***
Mean diastolic blood pressure 97.6 (10.1) 78.6 (8.4) ,0.001***
*41/201 indicates 41 minor alleles (T in this case) and 201 major alleles for a total of 242.
**Differences in allele frequency evaluated with Chi square test.
***Differences between means evaluated with paired t test.
****Differences between discrete variables evaluated with McNemar’s Chi square test.
doi:10.1371/journal.pone.0071231.t002
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multiple variants are predicted to be located in regulatory active
regions (see Figures S1, S2 and Table S1). Review of the associated
variants in the UCSC genome browser, identified a liver EST
sequence BG616599 and evidence of transcription by RNA-seq
exclusively in the liver, in the region containing rs3093068. This
suggests that rs3093068 may possibly be located in the extended 39
untranslated region of the CRP transcript. This presents the
possibility that the variant could alter CRP mRNA stability of
miRNA binding to the CRP transcript. Another published study
by Choi et al. (2007) may also be highly relevant.[42] They
investigated the mechanism of TNF-induced CRP expression and
found that b-catenin enhanced the expression of CRP mRNA in
concert with the p50 subunit of NF-kB, subsequently identifying a
binding site for the b-catenin/TCF-4 complex in the downstream
region of CRP by chromosome conformation capture. The SNP
rs876538 is within 30 bp of one of the TCF-4 binding sites
identified by Choi et al. and therefore may have an impact on
CRP expression.
Discussion
Among many proposed theories related to the etiology of PE,
dysfunctional immune responses have played prominent roles.[43]
C-reactive protein is an important component of the innate
immune response and a large body of evidence has been
developed showing correlation between CRP levels and other
indicators of inflammatory states [29,44], as well as associations
with PE[45,46] and multiple cardiovascular phenotypes with
possible relevance to PE.[47] We previously identified an
association between rs1205 in CRP with severe PE in this cohort
of American Indian women.[31] These findings prompted the
extension of our investigation into additional variants in CRP for
association with PE in this higher risk risk population. Of the ten
IBC array SNPs with sufficient prevalence to allow analysis of their
relation with PE, there were two (rs3093068 and rs876538) that
were PE-associated at nominal significance using both McNemar
chi-square and logistic analysis; and three (rs876538, rs2794521,
rs3091244) attained Bonferroni adjusted significance in the chi
square, paired analysis. An additive risk score using these two
alleles showed Bonferroni adjusted significance in both chi square
(all and severe cases) and significant P values of 0.009 and 0.01 in
univariate and multivariate logistic analysis respectively. While
these variants in the CRP gene have been investigated for their
association with other inflammatory conditions, to our knowledge,
this is the first report of association between these two SNPs (in
addition to rs1205) and PE. The replication of these findings in a
Table 3. Genotypes associated with case/control (matched-pair) status.
Discord pairs* Discord pairs
dbSNP allele Maj Dom Alter p value allele Min Dom alter p value total pairs
rs12068753 T 28 15 0.07 A 0 0 NA 177
rs1341665 G 33 33 0.90 A 24 21 0.77 152
rs12084589 C 27 15 0.09 A 0 0 NA 176
rs3093059 T 0 0 NA C 28 15 0.07 177
rs2794521 T 7 5 0.77 C 25 51 0.004 153
rs3091244 C 59 29 0.002 T 13 24 0.10 177
rs1800947 C 1 0 1.00 G 16 8 0.15 172
rs3093068 C 0 0 NA G 29 13 0.021 163
rs3093070 A 0 0 NA C 3 3 0.68 145
rs876538 C 8 6 0.789 T 40 82 ,0.001 270
risk score** yes 57 20 ,0.001
Severe Cases and Controls
rs12068753 T 19 11 0.201 A 0 0 NA 117
rs1341665 G 21 18 0.749 A 14 13 1.0 95
rs12084589 C 18 11 0.265 A 0 0 NA 116
rs3093059 T 0 0 NA C 19 11 0.201 117
rs2794521 T 5 5 0.752 C 19 35 0.041 106
rs3091244 C 34 23 0.185 T 11 17 0.348 117
rs1800947 C 0 0 NA G 9 5 0.423 115
rs3093068 C 0 0 NA G 22 9 0.031 108
rs3093070 A 0 0 NA C 3 2 0.149 102
rs876538 C 7 6 1.0 T 31 58 0.006 186
risk score yes 41 12 0.0001 108
*‘‘Discord pairs’’ indicates the number of case/control pairs that are discordant for a particular genotype ‘‘Maj Dom’’: where the major allele is dominant for the case.
‘‘Alter’’ indicates the alternate situation where the control genotype is dominant for the major allele. Similarly ‘‘Min Dom’’ indicates discordant pairs where the case
genotype is dominant for the minor allele. ‘‘Total pairs’’ shows the total number of matched pairs, including both concordant and discordant pairs. ‘‘NA’’ refers to ‘‘not
applicable’’.
**Risk score indicates the risk genotype from either rs3093068 (G allele dom) or rs876538 (C allele recess) is present, among pairs with both alleles available.
doi:10.1371/journal.pone.0071231.t003
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results.
The extent and specifics of genetic influences on serum CRP
levels remains unclear; but a number of studies have identified
important associations with various SNPs, [48–50] including those
identified in this study. The 1KGP has reported a rs3093068
minor allele frequency of 6.7% among 120 European chromo-
somes [51], consistent with the current study. Carriers of this
minor allele have increased levels of CRP, most notably in a
subcohort of Asian/Pacific Islanders, suggesting the existence of
ethnic variations in the relationship between rs3093068 and CRP
concentrations.[52] In terms of association with clinical pheno-
types, a haplotype tagged by rs3093068, rs1205 and another SNP
was associated with risk of myocardial infarction in a large
prospective study;[53] whereas a small, case/control study failed to
find a relationship between neovascular age-related macular
degeneration and rs3093068. [54] The lack of association with
this SNP in our replication population may be due to the use of a
proxy SNP that was in complete linkage disequilibrium in the
European population; but less so in both our discovery cohort
(r
2=0.792) and the Asian population referenced above (r
2=0.764
in 1000 G HapMap Asians (CHB/JPT)).[37] Another possibility is
that rs3093068 is truly not associated with PE in the European
replication population, due to the different genetic background.
The other SNP with significant findings of association in the
present study, rs876538, has a prevalence very similar to the
22.1% reported for Europeans.[55] Increases in CRP levels in a
predominantly older postoperative Caucasian male sample were
not associated with rs876538, but were associated positively with
rs3091244 and negatively with rs1800947. [56] The rs3091244
SNP did show association in our study during McNemar chi
square analysis; but this was not supported after multivariate
adjustment. The rs1800947 SNP failed to show any significant
association in this study. Another SNP (rs2808630) in linkage
disequilibrium with rs876538 (r
2=0.63, d9=1) affects CRP
expression.[57] However, rs876538 was associated, in an Austra-
lian population, with improved treatment response in neovascular
age-related macular degeneration. [58]
In evaluating the findings of the present analysis and
comparison with other association studies of CRP levels and PE,
consideration must be given to genetic background effects such as:
1) differences in linkage disequilibrium between populations,
causing discordant results due to the presence or absence of
linkage to an unknown causative SNP, 2) differences in power to
Table 4. Univariate, conditional logistic regression analysis of factors associated with pre-eclampsia.
Characteristic N pairs Model OR p Value
CRP, rs3093068, (G allele), All pre-eclampsia cases 163 Additive 1.973 0.063
Dominant 1.973 0.063
Recessive N.A.
CRP, rs3093068, (G allele), Severe pre-eclampsia 108 Additive 2.368 0.041
Dominant 2.368 0.041
Recessive N.A.
CRP, rs876538, (C allele), All pre-eclampsia cases 270 Additive 1.502 0.045
Dominant 0.803 0.746
Recessive 1.611 0.033
CRP, rs876538, (C allele), Severe pre-eclampsia 186 Additive 1.361 0.184
Dominant 0.890 0.866
Recessive 1.477 0.141
rs3093068,(dom) and rs876538 (recess) risk score, both =2, either =1,
neither =0
163 risk score 1.688 0.009
rs3093068,(dom) and rs876538 (recess) above with severe PE 108 risk score 1.820 0.012
Age at delivery (per year) 270 0.996 0.843
Nulliparity (yes) 270 3.026 0.001
Gestation at first prenatal visit (per week from LMP) 178 0.978 0.190
Weight at first prenatal (per pound) 265 1.008 0.001
Body-Mass index (per unit Kg/meter
2) 265 1.054 0.001
Birth weight of infant (per gram) 147 0.999 0.001
Mother’s educational attainment (per year) 144 0.948 0.407
Maternal smoking (mean cigarettes smoked per day) 144 0.985 0.091
Gestational diabetes in current pregnancy (yes) 189 2.369 0.034
Boston and Philadelphia replication cohort, univariate logistic regression
Characteristic Cases/Controls Model OR p Value
CRP, rs 12068753 (A allele) for rs3093068 178/424 Additive 0.940 0.810
CRP, rs876538 (C allele) 178/423 Additive 1.547 0.011
CRP, rs1205 (T allele) 173/410 Additive 1.037 0.787
doi:10.1371/journal.pone.0071231.t004
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SNP of interest and 3) differential effects of the SNP of interest
based on interaction between the SNP of interest and an unknown
genetic variant with population-specific effects. Furthermore,
environmental factors can vary substantially between populations
and overwhelm the genetic signal, resulting in a loss of power, or
differential SNP-environment effects may influence the compar-
ison between populations. The adjustment for age, BMI and
gender in the present primary study may increase the likelihood
that the identified SNPs are influencing the immune response,
provided the modeled adjustment is accurate (i.e., first or second
order, or bimodal distributions may complicate the adjustment).
Although the heritability of CRP in another American Indian
population was found to be approximately 40% [59], there are
clearly a number of environmental factors impacting CRP levels.
The differential genetic and environmental effects on CRP serum
levels and clinical phenotypes are complex and remain unclear.
Clinical correlates including age, gender, BMI and BP were more
strongly associated with CRP levels than CRP SNPs in a large
cohort study of older Americans. Although rs876538 was included
in the analysis, it did not retain significance after multivariate
adjustment.[60]
The association between PE and inflammation has suggested
CRP levels as an important marker of this disease. [45,53,61,62]
Although there have been contrary reports,[63] including
evidence that the association may be seen only among lean
individuals,[64] a systematic review found suggestive evidence for
a prospective association between PE and elevated CRP which
was further modified when BMI was also increased.[46]
None of these purported associations, either cross-sectional or
prospective, prove that CRP is in the direct causal chain for PE, it
may be simply a marker of inflammation initiated by current or
still latent primary factors causing PE. The results of genetic
association studies such as this do contribute to our understanding,
in so far as the genetic variants are obviously present prior to the
establishment of any disease state. None the less, CRP variants
could still be either simple biomarkers, indicating a genetic
heightened sensitivity to the primary cause(s) of PE; or they could
be involved in pathogenesis as a modifier of response to an actual
cause of the condition. Two publications make a similar
observation when they suggest that CRP may be an intermediary
between BMI and hypertension.[61,65] Our previous findings
demonstrated an association of PE with rs1205 genotypes linked to
increased CRP levels, and are consistent with these studies. The
present study reveals evidence of associations between rs3093068
and rs876538 by a number of statistical measures, and while some
measures and models in the primary study are marginal in
significance, possibly due to study size and resulting borderline
power; the finding of a significant association in the replication
study provides additional evidence for the rs876538 association.
The lack of replication seen in the European ancestry samples for
rs1205 and rs3093068 may be due to differences in LD, or
unidentified phenotypic or environmental factors differing be-
tween populations.
Limitations of this study include limited power due to modest
sample size which is common to many investigations of PE,
although we emphasize that this is the largest PE study to date in
American Indians. Our multivariate logistic regression results
nearly reached study-wide significance after conservative, Bonfer-
roni adjustment for multiple testing only for the additive risk score
among severe cases. However, our previous finding of association
with rs1205 in this cohort, replication of results for rs876538 in
another population, and nominally significant findings in two of
ten tested SNPs, certainly suggests that the CRP gene warrants
further investigation. The fact that 24% of our controls were
recruited in a slightly different fashion and the difference between
case and control delivery dates was slightly over 9 days greater
than the other case/control pairs could have possibly introduced a
subtle, unrecognized bias, although concern for seasonality effects
of this degree seems unwarranted. The inability to adjust the
replication sample for clinical covariates was also a limitation but
we again emphasize that this is a unique study population.
Strengths of this study include a well-defined phenotype of PE and
the study design which employed an unbiased ascertainment of
cases and controls. The fact that the present study focused on CRP
gene variants rather than circulating CRP levels, should reduce
Table 5. Multivariate, conditional logistic regression analysis of factors associated with pre-eclampsia and severe pre-eclampsia.
Pre-eclampsia Severe Pre-eclampsia
MODEL 1, all of following*
OR P value OR P value
Age at delivery 1.053 0.076 1.052 0.166
Nulliparous 5.600 0.001 4.170 0.001
BMI 1.061 0.002 1.059 0.001
Gestational diabetes 1.684 0.278 2.241 0.166
MODEL 2, Age, nulliparity,and BMI,plus each of the following individually:**
CRP, rs3093068, (G allele additive) 1.904 0.124 2.587 0.050
CRP. rs3093068, (G allele recessive) N.A. N.A.
CRP, rs3093068, (G allele dominant) 1.904 0.124 2.587 0.050
CRP, rs876538, (C allele additive) 1.524 0.060 1.319 0.271
CRP, rs876538, (C allele recessive) 1.583 0.066 1.380 0.267
CRP, rs876538, (C allele dominant) 0.532 0.404 0.699 0.637
rs3093068,(G dom) and rs876538 (C recess) additive risk score, both =2, either =1,
neither =0
1.779 0.016 2.035 0.013
*Covariates showing univariate significance, plus age, which interacts with nulliparity.
doi:10.1371/journal.pone.0071231.t005
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expression.
Our findings related to these 2 previously unreported CRP gene
variants provide suggestive findings that may warrant further
expression studies and replication in other cohorts. Although there
is a significant correlation between these SNPs, the combined
strength of association for both rs3093068 and rs876538 with
severe PE risk were enhanced, compared with either assessed
separately suggesting that these gene variants do not merely share
a haplotype. Until our publication reporting the significant
association of the CRP SNP rs1205[31], associations of CRP
with PE were limited to the circulating protein product. In this
study, we extended our investigation reporting two additional
SNPs, rs3093068 and rs876538, likely associated with PE in an
American Indian population and evidence for a similar association
of rs876538 in those of European ethnicity. Our findings,
combined with clinical correlates, may contribute the prioritiza-
tion of biological processes underpinning this devastating disease
in women at risk for developing PE.
Supporting Information
Figure S1 Genomic context of CRP, Chromosome 1
extended locus. Data is visualized using the UCSC human
genome browser and custom track data, presented in the following
order: i) AMR LD proxy SNPs (r2 LD.0.5), ii) ASN LD proxy
SNPs (r2 LD.0.5), iii) CEU LD proxy SNPs (r2 LD.0.5), iv)
Directly associated SNPs, v) Liver EST sequence BG616599, vi)
Published studies of CRP including downstream regions of
functional characterization, vi) ENCODE: RNA-seq assayed in
9 cell lines, vii) ENCODE: H3K4Me3 histone marks representing
probable promoter activity, viii) ENCODE: H3KMe1 histone
marks presenting probable regulatory enhancer activity, ix)
ENCODE: H3K27Ac histone marks presenting probable regula-
tory enhancer activity, x)ENCODE: DNase I hypersensitive
regions, indicating DNA binding activity, xi) Liver tissue RNA-
seq from the Burge lab, xii) Mammalian conservation.
(TIF)
Figure S2 Chromosome 1 directly associated SNPs. Data
is visualized using the UCSC human genome browser and custom
track data, presented in the following order: i) AMR LD proxy
SNPs (r2 LD.0.5), ii) ASN LD proxy SNPs (r2 LD.0.5), iii) CEU
LD proxy SNPs (r2 LD.0.5), iv) Directly associated SNPs, v)
Liver EST sequence BG616599, vi) Published studies of CRP
including downstream regions of functional characterization, vi)
ENCODE: RNA-seq assayed in 9 cell lines, vii) ENCODE:
H3K4Me3 histone marks representing probable promoter activity,
viii) ENCODE: H3KMe1 histone marks presenting probable
regulatory enhancer activity, ix) ENCODE: H3K27Ac histone
marks presenting probable regulatory enhancer activity, x)EN-
CODE: DNase I hypersensitive regions, indicating DNA binding
activity, xi) Liver tissue RNA-seq from the Burge lab, xii)
Mammalian conservation.
(TIF)
Table S1 Further detail concerning SNPs shown in
Figure S2.
(XLS)
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